Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Psoriatic Arthritis

Gottlieb A, Menter A, Mendelsohn A et al.

Tufts Medical Center, Boston, MA, USA.

 Lancet 2009;373:633–40.

Editor’s note: Not all patients with psoriatic arthritis (PsA) respond to disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor-α (anti-TNF-α) agents. Interleukin-12 (IL-12) and IL-23 are thought to play a role in causing bone and joint damage in PsA. Ustekinumab is a human monoclonal antibody that binds a subunit shared by IL-12 and IL-23 and prevents these cytokines from binding to their receptors. This Phase II study explored the hypothesis that this agent might therefore be effective in the treatment of PsA.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles